Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024Benzinga • 11/07/24
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across AfricaGlobeNewsWire • 11/06/24
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst UpgradesZacks Investment Research • 10/25/24
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBSGlobeNewsWire • 10/25/24
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024GlobeNewsWire • 10/23/24
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid EpidemicGlobeNewsWire • 10/08/24
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness EffortsGlobeNewsWire • 09/26/24
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox VaccinesBenzinga • 09/25/24
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness EffortsGlobeNewsWire • 09/25/24
Emergent BioSolutions Announces Agreement to Settle Securities Class Action LitigationGlobeNewsWire • 09/13/24
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for EbolaGlobeNewsWire • 09/12/24
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial ProfileGlobeNewsWire • 09/03/24
Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox VaccineInvestors Business Daily • 08/30/24
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency PreparednessGlobeNewsWire • 08/30/24
Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox InfectionBenzinga • 08/30/24
Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other RegionsGlobeNewsWire • 08/29/24
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora PharmaceuticalsGlobeNewsWire • 08/20/24